Check for updates

#### **OPEN ACCESS**

EDITED BY Stephane Avril, Institut Mines-Télécom, France

#### REVIEWED BY Avik Basu, School of Public Health and Harvard University, United States Jai-Wun Park, Charité University Medicine Berlin, Germany Sebastian Bannasch, Steinbeis Foundation, Germany

\*CORRESPONDENCE Jian-fang Luo 🛙 jianfangluo@sina.com

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 13 April 2025 ACCEPTED 30 June 2025 PUBLISHED 22 July 2025

#### CITATION

He W-f, Zeng L-h, Xie N-s, Liu H-x, Cui W-m, Wang Y, Zhang Z-j, Ye G-l, Qin Z-y, Guo Z-q, Ma J and Luo J-f (2025) Effectiveness of magnetocardiography as a non-invasive tool for functional assessment of myocardial ischemia in patients with stable coronary artery disease.

Front. Med. Technol. 7:1611046. doi: 10.3389/fmedt.2025.1611046

#### COPYRIGHT

© 2025 He, Zeng, Xie, Liu, Cui, Wang, Zhang, Ye, Qin, Guo, Ma and Luo. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Effectiveness of magnetocardiography as a non-invasive tool for functional assessment of myocardial ischemia in patients with stable coronary artery disease

Wen-fei He<sup>1†</sup>, Li-huan Zeng<sup>2†</sup>, Nan-shan Xie<sup>3†</sup>, Hao-xing Liu<sup>1,4</sup>, Wen-min Cui<sup>1</sup>, Ying Wang<sup>1</sup>, Zhi-jian Zhang<sup>1</sup>, Guan-lun Ye<sup>1</sup>, Zhi-ying Qin<sup>1</sup>, Zhi-qiang Guo<sup>1</sup>, Jun Ma<sup>5</sup> and Jian-fang Luo<sup>1,3\*</sup>

<sup>1</sup>Department of Cardiology, Guangdong Provincial People's Hospital's Nanhai Hospital, the Second People's Hospital of Nanhai District, Foshan, China, <sup>2</sup>Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China, <sup>3</sup>Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, <sup>4</sup>Department of General Practice, Guicheng Community Health Service Center of Nanhai District, Foshan, China, <sup>5</sup>R&D Department, Shenzhen Raysight Intelligent Medical Technology Corporation, Shenzhen, Guangzhou, China

**Background:** Identification of coronary ischemia in suspected coronary artery disease (CAD) remains challenging. Magnetocardiography (MCG) demonstrated comparably high diagnostic efficiency for detecting coronary ischemia in previous studies. However, limited evidence exists comparing MCG vs. computed tomography angiography-derived fractional flow reserve (CTFFR) in suspected CAD patients.

**Methods:** A total of 291 patients with CTA-confirmed diameter stenosis ranging from 30% to 90% were included and divided into two groups based on the CTFFR values, the stable coronary artery disease (SCAD) group ( $\leq$ 0.8) and the non-SCAD group (>0.8). Magnetic field map (MFM) parameters were employed to construct a diagnostic model. The performance of the models was evaluated using receiver operating characteristic (ROC) curves, accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

**Results:** Patients with SCAD showed a mean MCG score of  $5.6 \pm 2.9$ , while the non-SCAD group demonstrated a mean score of  $2.0 \pm 1.9$  (P < 0.001). The area under the curve (AUC) for ROC analysis was 0.824 (95% CI: 0.772-0.877). Point 5 was selected as the operational cutoff value providing a favorable balance of sensitivity and specificity. Ultimately, MCG score yielded a sensitivity of 69.6%, specificity of 87.9%, PPV of 72.7%, NPV of 86.2%, and accuracy of 82.1%.

**Conclusions:** Compared to CTFFR, MCG demonstrated superior specificity and moderate sensitivity for detecting CAD in patients with diameter stenosis CTA ranging from 30% to 90%. It may provide an alternative to functional evaluation prior to invasive or radiation exposure methods.

#### KEYWORDS

magnetocardiography (MCG), angiography-derived fractional flow reserve, stable coronary artery disease (SCAD), coronary ischemia, assessment

# Highlights

- What is already known on this topic Currently, certain diagnostic measures with inherent limitations are employed to diagnose SCAD. MCG is established as an efficient tool for cardiac disease diagnosis. An evidence gap persists regarding MCG vs. CTFFR in assessing myocardial ischemia.
- What this study adds Compared with CTFFR, MCG demonstrated superior specificity and moderate sensitivity for detecting CAD in patients with CTA-confirmed diameter stenosis ranging from 30% to 90%.
- How this study might affect research, practice, or policy MCG is a simple and effective method for detecting myocardial ischemia.

# Introduction

Coronary artery disease (CAD) remains the leading cause of death worldwide and is associated with substantial individual, economic, and societal burdens. Only a minority of patients present mild symptoms in stable coronary artery disease (SCAD) (1). To lower the coronary deaths in asymptomatic adults, numerous measurements of risk factors and markers, as well as stress tests, are employed as screening investigations.

Fractional flow reserve (FFR) assesses physiological stenosis severity. However, coronary angiography in low-risk patients imposes unnecessary burden and risk, while, FFR, which requires specialized pressure guidewires, is both technically complex and costly. Routine electrocardiogram and echocardiography demonstrate relatively high diagnostic performance for acute myocardial infarction, but are insufficient for SCAD. Although the exercise treadmill testing, stress echocardiography, cardiac magnetic resonance imaging (CMR) and single-photon emission computed tomography (SPECT) can also evaluate myocardial ischemia, they cannot assess coronary artery stenosis, moreover, these methods present several limitations, including complex procedures, high technical demands, substantial costs, and potential radiation exposure (2, 3). Therefore, a non-invasive, safe and simple method is required to facilitate the early diagnosis of stable coronary artery disease.

Computed tomography angiography-derived fractional flow reserve (CTFFR) is a novel noninvasive approach for precisely localizing ischemia-causing coronary stenosis. It utilizes computational fluid dynamics (CFD) to calculate "3-vessel" FFR from standard coronary computed tomography angiography (CCTA) images without requiring additional imaging or vasodilators (4, 5). Furthermore, the PLATFORM study demonstrates that CTFFR enhances diagnostic certainty by reducing invasive coronary angiography cancellations by 61% and significantly lowering the rate of detecting non-obstructive CAD (6).

Magnetocardiography (MCG) measures changes in the heart's electromagnetic field, which are altered in the diseased hearts, likely due to modifications in the trajectory or number of moving ions or electrons. An objective scoring system facilitates interpretation and comparison of results. Given the absence of radiation, MCG is ideal for screening and frequent monitoring of heart conditions, especially in CAD (7, 8). MCG detects minute electrophysiological changes that lead to abnormal currents, especially occurring in early ischemia, enabling early CAD diagnosis (9).

Nowadays, MCG has shown certain potential in the diagnosis of CAD (10), arrhythmia and inflammatory cardiomyopathy (11), and has become a research hotspot worldwide. However, most of the relevant studies are exploratory studies, with a small sample size and lacking in-depth research. Also, the performance of MCG in patients with relatively low risk of myocardial ischemia during routine check-ups is still inconclusive. This study aims to use the latest MCG equipment to assess myocardial ischemic function in patients with stable coronary artery disease.

# **Methods**

## Study design and population

This was a single-center, prospective, observational cohort study that consecutively enrolled 355 patients with suspected SCAD at Guangdong Provincial People's Hospital's Nanhai Hospital, comprising 281 male patients and having a mean age of 52.3 years. To evaluate the accuracy of MCG in detecting hemodynamically significant SCAD during routine check-ups, CTFFR was utilized as the reference standard for noninvasive examinations.

For adults with cardiovascular risk factors or suspected symptoms during routine check-ups, CCTA was used as the primary screening tool for early-stage SCAD. Patients with 30% to 90% diameter stenosis confirmed by CCTA in at least one major epicardial coronary artery were prospectively enrolled in this study. Generally, patients with >90% stenosis on CCTA have a clear clinical indication for invasive coronary angiography, while those with <30% stenosis can be safely ruled out from severe myocardial ischemia (12). To ensure the accuracy, safety, and specificity of detection, patients who had a history of any of the following conditions, including revascularization, acute myocardial infarction, hypertrophic or dilated cardiomyopathy, or complete bundle branch block, were excluded from the study. Additionally, notably, people with implanted metallic devices (e.g., pacemaker, ICDs) or inability to lie flat-precluding MCG examination-were excluded from recruitment. Patients with main coronary artery lesions and side branch lesions were excluded. After enrollment, all the patients underwent the MCG examination and CTFFR analysis before subsequent medical or interventional therapy. Those with CTFFR ≤0.8 were categorized

Abbreviations

SCAD, stable coronary artery disease; CCTA, coronary computed tomography angiography; CTFFR, computed tomography angiography-derived fractional flow reserve AUC, the area under the curve; SEN, sensitivity SPE, specificity; NPV, negative predictive value; PPV, positive predictive value; ACC, accuracy.

into the SCAD group, while the remaining subjects comprised the control group. Other related clinical data were extracted from the hospital information system. The flow chart outlining the study process is presented in Figure 1.

## MCG examination

The MCG scans were performed by an unshielded 9-channel MCG system (MD-U0-92001, Shanghai MEDI Instruments Ltd., Shanghai, China) as illustrated in Figure 2A. This equipment utilized superconducting quantum interference device (SQUID) sensors linked to second-order axial gradiometers to detect the extremely weak magnetic field generated by electrical activity of the heart. After removing all jewelry, electronic devices, and other metal objects, we sequentially acquire magnetic field signals at four distinct positions over the precordial region: superior right, superior left, inferior left, inferior right. The composite data from these four acquisition positions collectively generates a 36-point measurement grid. The whole examination process



Flow chart of the study. SCAD, stable coronary artery disease; CCTA, coronary computed tomography angiography; MCG, magnetocardiography; CTFFR, CTA-derived fractional flow reserve; AMI, acute myocardial infarction; PCI, percutaneous coronary intervention; BBB, bundle branch block.



lasted for approximately 5 min at a sampling rate of 1,000 Hz, with simultaneous recording of the ECG lead-II as reference. The raw signals were then baseline-corrected, digitally filtered, and averaged to increase the signal-to-noise ratio. Magnetic field maps (MFMs) were digitally plotted based on the iso-field contour maps at each millisecond of one cardiac cycle (Figure 2B). 8 parameters derived from 5 categories of MFM features were evaluated for each patient. The validity of these 5 feature categories has been established in prior research, with Cui et al. demonstrating their efficacy in predicting the risk of severe coronary artery stenosis among patients presenting with angina-like symptoms (13). In this study, however, we aimed to investigate whether these parameters could be applied to general screening populations.

#### CCTA assessment

The CCTA images [Revolution HD (GE)] were parsed by two radiologists with more than five years of experience, and the location of the target lesion on CCTA was demarcated jointly by the radiologists and the cardiologist. The percentage diameter stenosis of the target lesion was quantified using offline quantitative coronary CT angiography software (Syngo-via, Siemens Healthineers, Forchheim, Germany). Curved multiplanar reconstructions, maximum intensity projections, and volume rendering techniques were employed to generate diagnostic images for interpretation (14).

### **CTFFR** measurement

CTFFR analysis was performed using a dedicated software (RuiXin-CTFFR, Raysight Inc., Shenzhen, China). This software employs CFD to calculate CTFFR values based on the CCTA images. First, the initial segmentation model of the entire coronary artery was extracted, from which each coronary artery centerline and contour were obtained by the region growth algorithm. The extracted coronary artery contours were subsequently connected and smoothed to facilitate the reconstruction of a threedimensional (3D) model. Using the morphological data extracted from the CT imaging and a statistical prediction model incorporating the patient's baseline characteristics (including allometric growth principles), patient-specific physiological parameters were determined. An unstructured mesh was then generated on the 3D coronary model, with the blood flow modeled as an incompressible Newtonian fluid. The incompressible Navier-Stokes equations were subsequently solved using a finite element algorithm, enabling the calculation of pressure and velocity values at each grid point within the 3D coronary model, ultimately yielding the final CTFFR measurements (15).

#### Statistical analysis

With  $\alpha = 0.025$  and  $\beta = 0.1$ , based on previous literature reporting a diagnostic accuracy of 85% for the CTFFR examination (16), we set the non-inferiority margin at 5%,

meaning that the diagnostic accuracy of MCG should be at least 80%. It was calculated that at least 169 samples are required to undergo both MCG and CT-FFR examinations. Considering the dropout rate of 20%, it was finally estimated that at least 211 samples are required for this clinical trial.

Continuous variables were expressed as means  $\pm$  standard deviations (SD). For normally distributed measurement data, *T*-test was used to compare the differences between the two groups. For non-normally distributed measurement data, Mann–Whitney *U*-test was used for group comparisons. Count data were expressed as the number of cases and composition ratio (%), and the chi-square test was used for comparison between groups. The diagnostic value of MCG score was assessed using receiver operating characteristic (ROC) curve analysis. The optimal cutoff value for the score was determined by Youden's J Index, defined as: Youden's J Index = Sensitivity + Specificity - 1. Statistical analysis evaluation was conducted using SPSS 23.0 and R 4.2.2 software. A significance level of *P* < 0.05 was considered statistically significant.

## **Ethics declarations**

The study was approved by the Hospital Ethics Committee and registered at https://www.ClinicalTrails.gov (NCT06123728). Written informed consents were obtained from each patient before enrollment.

## Results

#### Patient characteristics

Among 355 patients with 30%–90% diameter stenosis on CCTA between April 2023 and December 2023, 21 patients were excluded based on medical history (6 had prior AMI or prior PCI, 15 had a bundle branch block). Additionally, 4 patients were unavailable for CTFFR analysis and 14 patients had uninterpretable MCG data due to noise interference, these 18 patients were also excluded. Furthermore, 25 patients were excluded due to side branch lesions. Ultimately, a total of 291 patients were recruited. All the patients were categorized into two groups based on their CTFFR (threshold  $\leq$ 0.80): the SCAD group (N = 92) and the non-SCAD group (N = 199) (Figure 1).

The baseline characteristics are summarized in Table 1. The median age (53 years vs. 51 years, P = 0.012) and the median BMI (26.51 kg/m<sup>2</sup> vs. 25. 10 kg/m<sup>2</sup>, P = 0.022) were higher in the SCAD group compared to the non-SCAD group.

Hypertension was more prevalent in the SCAD group (55.3% vs. 30.3%, P < 0.001). Other clinical characteristics showed no significant differences between the two groups.

## Performance of MCG score

Patients with SCAD showed a mean MCG score of  $5.6 \pm 2.9$ , while the non-SCAD group had a mean score of  $2.0 \pm 1.9$  (*P* < 0.001). The area under the curve (AUC) for ROC analysis was

Characteristic	Overall ( <i>N</i> = 291)	SCAD ( <i>N</i> = 199)	Non-SCAD ( <i>N</i> = 92)	<i>P</i> -value
Male, <i>n</i> (%)	281 (96.6)	192 (96.5)	89 (96.7)	1
Age (years)	$52.3 \pm 4.8$	$51.8 \pm 4.3$	$53.4 \pm 5.6$	0.012
BMI (kg/m <sup>2</sup> )	$25.8 \pm 3.6$	25.5 ± 3.7	$26.4 \pm 3.3$	0.022
Typical symptoms, n (%)	34 (13.1)	24 (13.1)	10 (13.0)	0.987
Current smoker, n (%)	150 (54.9)	102 (54.3)	48 (56.5)	0.834
Hypertension, n (%)	104 (38.1)	57 (30.3)	47 (55.3)	<0.001
Hyperlipidemia, n (%)	100 (36.6)	73 (38.8)	27 (31.8)	0.324
Diabetes, n (%)	44 (16.1)	27 (14.4)	17 (20.0)	0.32
MCG score	$3.2 \pm 2.8$	$5.6 \pm 2.9$	$2.0 \pm 1.9$	<0.001

TABLE 1 Baseline characteristics of the study population.

SCAD, stable coronary artery disease.



0.824 (95% CI: 0.772–0.877), shown in Figure 3. By comparing the Youden's J Index across all score points, we identified 1.89 as the cutoff value with the maximum Youden's J Index. However, given the considerable gap between this optimal cutoff and the next higher available threshold (5.83), we selected point 5 as the operational cutoff, which provided favorable sensitivity-specificity balance. MCG score achieved a sensitivity of 69.6%, specificity of 87.9%, PPV of 72.7%, NPV of 86.2%, and accuracy of 82. 1%. The performance metrics of MCG score are summarized in Table 2.

## MCG results in different subgroups

The degree of stenosis in each major epicardial coronary artery on CCTA and the CTFFR values per vessel are presented in Table 3. The prevalence of obstructive CAD by CCTA differed substantially from the prevalence of ischemia by CTFFR. 132 (45.4%) patients had at least one vessel with  $\geq$ 50% diameter stenosis, while only 92 (31.6%) patients exhibited CTFFR  $\leq 0.8$ . Furthermore, LAD was the most prevalent lesion site, involving 95 patients with stenosis  $\geq 50\%$  and 77 patients with CTFFR  $\leq 0.80$ .

Compared with CCTA results, the concordance rates of CTFFR and MCG with coronary stenosis were 78.7% (229/291) and 66.3% (193/291), respectively. In contrast, CTFFR results showed greater concordance with MCG evaluation, with a high concordance rate of 82.1% (239/291). Among patients with CCTA stenosis <50%, 133 individuals (83.6%) had concordant CTFFR and MCG results. Conversely, among patients with CCTA stenosis  $\geq$ 50%, 106 individuals (80.3%) had concordant CTFFR and MCG results (Table 4).

## Discussion

To the best of our knowledge, this was the first study to evaluate the diagnostic performance of the MCG against CTFFR.

TABLE 2	The	performance	of t	he	MCG	score.
---------	-----	-------------	------	----	-----	--------

Parameter	Estimated value	95% confidence Interval
AUC	0.824	(0.772–0.877)
SEN	0.696	(0.590-0.785)
SPE	0.879	(0.824–0.920)
PPV	0.727	(0.620-0.814)
NPV	0.862	(0.805–0.905)
ACC	0.821	(0.772-0.864)

AUC, area under the curve; SEN, sensitivity; SPE, specificity; NPV, negative predictive value; PPV, positive predictive value; ACC, accuracy.

TABLE 3 Vessel characteristics by CCTA and FFR<sub>CT</sub>.

Vessel characteristic	LAD, n (%)	LCX, n (%)	RCA, n (%)	The most severe vessel, <i>n</i> (%)	
CCTA results					
Stenosis <50	196 (67.4)	254 (87.3)	247 (84.9)	159 (54.6)	
50 ≤stenosis <70	69 (23.7)	30 (10.3)	32 (11.0)	97 (33.3)	
Stenosis ≥70	26 (8.9)	7 (2.4)	12 (4.1)	35 (12.0)	
FFR <sub>CT</sub> results					
FFR <sub>CT</sub> >0.8	214 (73.5)	271 (93.1)	265 (91.1)	199 (68.4)	
$FFR_{CT} \leq 0.8$	77 (26.5)	20 (6.9)	26 (8.9)	92 (31.6)	

CCTA, coronary computed tomography angiography;  $\rm FFR_{CT},$  computed tomography angiography-derived fractional flow reserve; LAD, left coronary artery; LCX, left circumflex artery; RCA, right coronary artery.

TABLE 4 MCG results in different subgroups of CCTA and FFR<sub>CT</sub>.

Subgroup	MCG (–), n	MCG (+), n
Stenosis <50% & FFR <sub>CT</sub> >0.8	127	21
Stenosis < 50% & FFR_{\rm CT} $\leq 0.8$	5	6
Stenosis $\geq$ 50% & FFR <sub>CT</sub> >0.8	48	3
Stenosis $\geq$ 50% & FFR <sub>CT</sub> $\leq$ 0.8	23	58

CCTA, coronary computed tomography angiography;  $FFR_{CT}$ , computed tomography angiography-derived fractional flow reserve.

The main finding of our analysis was that, compared to CTFFR, MCG showed high sensitive and specific for predicting myocardial ischemia in patients with cardiovascular risk factors or suspected symptoms who had 30%–90% diameter stenosis on CCTA.

MCG is a non-contact, non-invasive, non-radiation method to detect myocardial ischemia by recording magnetic fields generated by cardiac electrical activity (17). Previous studies confirmed that MCG demonstrates high sensitivity and specificity, compared to other diagnostic modalities, such as electrocardiography (ECG), SPECT, and FFR (18–20). An evidence gap exists regarding the diagnostic value of CAD between MCG and CTFFR. Additionally, nearly all the studies enrolled high-risk patients with CTA- or angiographically-confirmed CAD, or classic with angina pectoris, while evidence for MCG in low-risk patients remains limited (21, 22). Lastly, when interpreting previous results, small sample size limitations cannot be overlooked (23). Thus, conducting this study to evaluate MCG's diagnostic performance against CTFFR in patients with 30%–90% diameter stenosis on CCTA was meaningful.

In the current study, we achieved a sensitivity of 69.6%, specificity of 87.9%, PPV of 72.7%, NPV of 86.2%, and accuracy of 82. 1%. Our finding was different from many previous studies considering MCG as a highly sensitive but less specific method (24-26). First, low-risk suspected CAD patients comprised most enrolled participants. Patients in our study had low rates of typical symptoms, hypertension, hyperlipidemia, and diabetes. However, when reviewing previous studies, the high risks mentioned above were considerably prevalent (24-26). Second, the coronary artery stenosis was less severe than other studies (26, 27). There were 132 patients with coronary stenosis  $\geq$ 50% but only 92 patients with CTFFR ≤0.8. Concurrently, the scatter plot of CTFFR values and MCG predictions showed us most CTFFR values >0.60. Thus, our cohort represented an unselected population, better reflecting real-world research. Based on these results, we believe that MCG could be a promising screening tool for individuals with low risk of CAD.

In addition to our study, other studies have also confirmed that MCG exhibits higher specificity and lower sensitivity. Van Leeuwen et al. found that MCG had a sensitivity of 85% in CAD patients with prior myocardial infarction vs. 68% in those without, and a specificity of 90% (21). Fenici et al. reported that two machine-learning techniques combined to identify abnormal MCG ventricular repolarization (VR) in 25 IHD patients and exclude VR abnormalities in 28 controls, yielding 75% sensitivity and 85% specificity (28). The results of these studies are consistent with our findings. In clinical practice, high specificity can guide decisions for further angiography, reducing the frequency of invasive procedures.

According to the subgroup result of CTFFR and MCG, for patients whose CTFFR was >0.8 and MCG was positive, the discrepancy may be explained by the incomplete correspondence between hemodynamic alterations in major coronary branches and the state of myocardial injury caused by ischemia. In SCAD, hemodynamic alterations may exhibit a temporal delay in inducing myocardial damage and electrophysiological alterations. During this subclinical phase, CTFFR may detect hemodynamic abnormalities while MCG remains negative due to the absence of established tissue injury. Furthermore, hemodynamic abnormalities in major coronary vessels are not the sole cause of myocardial ischemia. Coronary microvascular dysfunction (CMVD)-a structural and functional disorder affecting small arteries, arterioles, and capillaries-frequently induces myocardial ischemia despite normal hemodynamics in major coronary branches (29, 30), in the study by Quesada et al., MCG demonstrated the capability to detect CMVD through a 90-second non-invasive scan, eliminating the need for intravenous vasodilators or ionizing radiation (31). In such scenarios, CTFFR may yield negative results, whereas MCG could demonstrate positive findings.

In the present study, an approximately 21.3% rate of mismatch between CCTA and CTFFR was found. Among these mismatched data, MCG showed a positivity rate of 54.5% (6/11) with positive

10.3389/fmedt.2025.1611046

mismatch (CTFFR ≤0.8, CCTA <50%), while demonstrating a positivity rate of 5.9% (3/51) with negative mismatch (FFR>0.8, CCTA  $\geq$ 50%), which indicated a high correlation between MCG and hemodynamically significant lesions. This is like the previous work by Park that MCG could accurately detect CAD vs. invasively determined FFR with a sensitivity of 86.7% and specificity of 73.9% (20). Considering the increasing need for early detection of ischemia in people at high risk of cardiovascular disease, MCG has been proposed as a noninvasive and contactless technique for functional diagnosis of the heart (32, 33). ECG relies on horizontal body surface potentials, making it vulnerable to signal cancellation that masks tangential/vortex currents. MCG directly measures perpendicular magnetic fields from cardiac activity. Tangential currents' magnetic fields are easily captured by sensors. Though electrically undetectable due to cancellation, vortex currents still generate measurable percardial magnetic fields via the right-hand rule (34, 35), MCG has the potential to benefit the assessment of suspected patients without CAD. Based on the application of artificial intelligence in the evaluation of disease, techniques like machine learning methods were implemented to automate diagnosis (36). In the previous study, back-propagation neural network (BNN) and direct kernel self-organizing map (DK-SOM) were applied to explore the IHD pattern recorded by MCG and exhibited accuracy of 74.5% and 80.4% respectively (37).

In terms of convenience and resource utilization, the implementation of an MCG pathway could significantly reduce patients' length of stay, and it just need 10 min to finish the assessment of the myocardial ischemia. Besides, compared to other measures, MCG yielded significantly higher patients' satisfaction (38, 39). Furthermore, given the substantial number of patients presenting with chest pain in outpatient and emergency departments, magnetocardiography (MCG) holds significant potential as a non-invasive diagnostic tool. When used complementarily to established modalities such as CCTA and SPECT (40, 41), MCG may effectively reduce both misdiagnosis rates and unnecessary exposure to surgical or other invasive procedures (42).

## Limitation

Several limitations should be acknowledged. Firstly, it was a single-center study conducted in China, the results might not be applied to whole population. Secondly, it is noted that the vast majority of patients in the current study were male. Though such a sex bias could not be ignored, the principle of MCG was to record magnetic fields generated by the electrical activity and there was no evidence revealing a difference in sex subgroup in the field of MCG. Thus, we recognized that sex would not change the final results. Thirdly, we were lack of the results of coronary angiography and FFR regarded as the golden standard of functional evaluation. Lastly, there are only 35 patients whose stenosis  $\geq$ 70 confirmed by CCTA, the small sample of this subgroup might contribute to the low sensitivity.

# Conclusion

Compared to CTFFR, MCG yielded a good specificity and acceptable sensitivity for the detection of CAD in patients whose diameter stenosis CTA was confirmed from 30% to 90%. It may provide an alternative to functional evaluation before other invasive or radiation exposure methods. Further studies are warranted to determine the role of MCG in this context.

# Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

# Ethics statement

The studies involving humans were approved by Research Ethics Committee of Guangdong Provincial People's Hospital's Nanhai Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

# Author contributions

W-fH: Conceptualization, Writing – review & editing. L-hZ: Methodology, Writing – original draft. N-sX: Writing – original draft. H-xL: Resources, Writing – review & editing. W-mC: Software, Writing – review & editing. YW: Data curation, Writing – review & editing. Z-jZ: Investigation, Writing – review & editing. G-lY: Validation, Writing – review & editing. Z-yQ: Visualization, Writing – review & editing. Z-qG: Supervision, Writing – review & editing. JM: Formal analysis, Writing – review & editing. J-fL: Funding acquisition, Project administration, Writing – review & editing.

# Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Guangdong Provincial Clinical Research Center for Cardiovascular Disease (2020B1111170011), National Natural Science Foundation of China (82200519), Natural Foundation of Guangdong Province, China (22022A1515010897), Medical Scientific Research Foundation of Guangdong Province, China (A2021348), and Self-Funded Scientific And Technological Innovation Project of Foshan (2220001005479).

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Al-Lamee RK, Foley M, Rajkumar CA, Francis DP. Revascularization in stable coronary artery disease. *BMJ*. (2022) 337:e067085. doi: 10.1136/bmj-2021-067085

2. Kozlov SG, Chernova OV, Gerasimova EV, Ivanova EA, Orekhov AN. Noninvasive testing for diagnosis of stable coronary artery disease in the elderly. *Int J Mol Sci.* (2020) 21(17):6263. doi: 10.3390/ijms21176263

3. Balfour PC Jr., Gonzalez JA, Kramer CM. Non-invasive assessment of low- and intermediate-risk patients with chest pain. *Trends Cardiovasc Med.* (2017) 27(3):182–9. doi: 10.1016/j.tcm.2016.08.006

4. Taylor CA, Fonte TA, Min JK. Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve: scientific basis. *J Am Coll Cardiol.* (2013) 61(22):2233–41. doi: 10.1016/j.jacc.2012. 11.083

5. Min JK, Taylor CA, Achenbach S, Koo BK, Leipsic J, Norgaard BL, et al. Noninvasive fractional flow reserve derived from coronary CT angiography: clinical data and scientific principles. *JACC Cardiovasc Imaging.* (2015) 8(10):1209–22. doi: 10.1016/j.jcmg.2015.08.006

6. Douglas PS, Pontone G, Hlatky MA, Patel MR, Norgaard BL, Byrne RA, et al. Clinical outcomes of fractional flow reserve by computed tomographic angiographyguided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study. *Eur Heart J.* (2015) 36(47):3359–67. doi: 10.1093/eurheartj/ehv444

7. Heidecker B. Quantum sensors: detect heart disease sooner. Nature. (2023) 619(7970):465. doi: 10.1038/d41586-023-02247-8

8. Her AY, Dischl D, Kim YH, Kim SW, Shin ES. Magnetocardiography for the detection of myocardial ischemia. *Front Cardiovasc Med.* (2023) 10:1242215. doi: 10.3389/fcvm.2023.1242215

9. Baule G, McFee R. Detection of the magnetic field of the heart. Am Heart J. (1963) 66:95–6. doi: 10.1016/0002-8703(63)90075-9

10. Agarwal R, Saini A, Alyousef T, Umscheid CA. Magnetocardiography for the diagnosis of coronary artery disease: a systematic review and meta-analysis. *Ann Noninvasive Electrocardiol.* (2012) 17(4):291–8. doi: 10.1111/j.1542-474X.2012. 00538.x

11. Suwalski P, Golpour A, Musigk N, Wilke F, Landmesser U, Heidecker B. Case report: recurrence of inflammatory cardiomyopathy detected by magnetocardiography. *Front Cardiovasc Med.* (2023) 10:1225057. doi: 10.3389/fcvm. 2023.1225057

12. Curzen NP, Nolan J, Zaman AG, Norgaard BL, Rajani R. Does the routine availability of CT-derived FFR influence management of patients with stable chest pain compared to CT angiography alone?: the FFR(CT) RIPCORD study. *JACC Cardiovasc Imaging*. (2016) 9(10):1188–94. doi: 10.1016/j.jcmg.2015.12.026

13. Cui JG, Tian F, Miao YH, Jin QH, Shi YJ, Li L, et al. Accurate diagnosis of severe coronary stenosis based on resting magnetocardiography: a prospective, single-center, cross-sectional analysis. *J Geriatr Cardiol.* (2024) 21(4):407–20. doi: 10.26599/1671-5411.2024.04.006

14. Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the society of cardiovascular computed tomography guidelines committee. *J Cardiovasc Comput Tomogr.* (2014) 8(5):342–58. doi: 10.1016/j.jcct.2014.07.003

15. Cai Z, Yu T, Yang Z, Hu H, Lin Y, Zhang H, et al. Detecting lesion-specific ischemia in patients with coronary artery disease with computed tomography fractional flow reserve measured at different sites. *BMC Med Imaging.* (2023) 23(1):76. doi: 10.1186/s12880-023-01031-4

## Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

16. Chung JH, Lee KE, Nam CW, Doh JH, Kim HI, Kwon SS, et al. Diagnostic performance of a novel method for fractional flow reserve computed from noninvasive computed tomography angiography (NOVEL-FLOW study). *Am J Cardiol.* (2017) 120(3):362–8. doi: 10.1016/j.amjcard.2017.04.057

17. Yamada S, Yamaguchi I. Magnetocardiograms in clinical medicine: unique information on cardiac ischemia, arrhythmias, and fetal diagnosis. *Intern Med.* (2005) 44(1):1-19. doi: 10.2169/internalmedicine.44.1

18. Shin ES, Park SG, Saleh A, Lam YY, Bhak J, Jung F, et al. Magnetocardiography scoring system to predict the presence of obstructive coronary artery disease. *Clin Hemorheol Microcirc.* (2018) 70(4):365–73. doi: 10.3233/CH-189301

19. Wu YW, Lin LC, Tseng WK, Liu YB, Kao HL, Lin MS, et al. QTc heterogeneity in rest magnetocardiography is sensitive to detect coronary artery disease: in comparison with stress myocardial perfusion imaging. *Acta Cardiol Sin.* (2014) 30(5):445–54.

20. Park JW, Shin ES, Ann SH, Godde M, Park LS, Brachmann J, et al. Validation of magnetocardiography versus fractional flow reserve for detection of coronary artery disease. *Clin Hemorheol Microcirc.* (2015) 59(3):267–81. doi: 10. 3233/CH-141912

21. Van Leeuwen P, Hailer B, Lange S, Gronemeyer DH. Identification of patients with coronary artery disease using magnetocardiographic signal analysis. *Biomed Tech (Berl).* (2006) 51(2):83–8. doi: 10.1515/BMT.2006.015

22. On K, Watanabe S, Yamada S, Takeyasu N, Nakagawa Y, Nishina H, et al. Integral value of JT interval in magnetocardiography is sensitive to coronary stenosis and improves soon after coronary revascularization. *Circ J.* (2007) 71(10):1586–92. doi: 10.1253/circj.71.1586

23. Brisinda D, Meloni AM, Fenici R. First 36-Channel Magnetocardiographic Study of CAD Patients in an Unshielded Laboratory for Interventional and Intensive Cardiac Care. Berlin, Heidelberg: Springer Berlin Heidelberg (2003).

24. Shin ES, Chung JH, Park SG, Saleh A, Lam YY, Bhak J, et al. Comparison of exercise electrocardiography and magnetocardiography for detection of coronary artery disease using ST-segment fluctuation score. *Clin Hemorheol Microcirc.* (2019) 73(2):283–91. doi: 10.3233/CH-180485

25. Rong T, Shulin Z, Xiao H, Minfang T, Jian M, Shixin M, et al. Magnetocardiography-based ischemic heart disease detection and localization using machine learning methods. *IEEE Trans Biomed Eng.* (2019) 66(6):1658–67. doi: 10. 1109/TBME.2018.2877649

26. Steinberg BA, Roguin A, Watkins SP 3rd, Hill P, Fernando D, Resar JR. Magnetocardiogram recordings in a nonshielded environment-reproducibility and ischemia detection. *Ann Noninvasive Electrocardiol.* (2005) 10(2):152-60. doi: 10. 1111/j.1542-474X.2005.05611.x

27. Goernig M, Liehr M, Tute C, Schlosser M, Haueisen J, Figulla HR, et al. Magnetocardiography based spatiotemporal correlation analysis is superior to conventional ECG analysis for identifying myocardial injury. *Ann Biomed Eng.* (2009) 37(1):107–11. doi: 10.1007/s10439-008-9598-5

28. Fenici R, Brisinda D, Meloni AM, Sternickel K, Fenici P. Clinical Validation of Machine Learning for Automatic Analysis of Multichannel Magnetocardiography. Berlin, Heidelberg: Springer Berlin Heidelberg (2005).

29. van de Hoef TP, van Lavieren MA, Damman P, Delewi R, Piek MA, Chamuleau SA, et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. *Circ Cardiovasc Interv.* (2014) 7(3):301–11. doi: 10.1161/ CIRCINTERVENTIONS.113.001049 30. Lee JM, Jung JH, Hwang D, Park J, Fan Y, Na SH, et al. Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis. *J Am Coll Cardiol.* (2016) 67(10):1158–69. doi: 10.1016/j.jacc.2015.12.053

31. Ashokprabhu N, Ziada K, Daher E, Cho L, Schmidt CW, Roca Y, et al. Evaluation of coronary microvascular dysfunction using magnetocardiography: a new application to an old technology. *Am Heart J Plus.* (2024) 44:100424. doi: 10. 1016/j.ahjo.2024.100424

32. Steinisch M, Torke PR, Haueisen J, Hailer B, Gronemeyer D, Van Leeuwen P, et al. Early detection of coronary artery disease in patients studied with magnetocardiography: an automatic classification system based on signal entropy. *Comput Biol Med.* (2013) 43(2):144–53. doi: 10.1016/j.compbiomed.2012. 11.014

33. Kwon H, Kim K, Lee YH, Kim JM, Yu KK, Chung N, et al. Non-invasive magnetocardiography for the early diagnosis of coronary artery disease in patients presenting with acute chest pain. *Circ J.* (2010) 74(7):1424–30. doi: 10.1253/circj.cj-09-0975

34. McFee R, Baule GM. Research in electrocardiography and magnetocardiography. *Proc IEEE*. (1972) 60(3):290–321. doi: 10.1109/PROC.1972.8621

35. Dutz S, Bellemann ME, Leder U, Haueisen J. Passive vortex currents in magnetoand electrocardiography: comparison of magnetic and electric signal strengths. *Phys Med Biol.* (2006) 51(1):145–51. doi: 10.1088/0031-9155/51/1/011

36. Han X, Pang J, Xu D, Wang R, Xie F, Yang Y, et al. Magnetocardiographybased coronary artery disease severity assessment and localization using spatiotemporal features. *Physiol Meas.* (2023) 44(12). doi: 10.1088/1361-6579/ ad0f70

37. Huang DM, Chung TH, Hung Y, Lu F, Wu SH, Mou CY, et al. Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells. *Toxicol Appl Pharmacol.* (2008) 231(2):208–15. doi: 10.1016/j.taap.2008.04.009

38. Mace SE, Baugh C, Pena ME, Takla R. A comparison of magnetocardiography with noninvasive cardiac testing in the evaluation of patients with chest pain. *Am Heart J Plus.* (2025) 54:100541. doi: 10.1016/j.ahjo.2025.100541

39. Mace SE, Peacock WF, Stopyra J, Mahler SA, Pearson C, Pena M, et al. Accelerated magnetocardiography in the evaluation of patients with suspected cardiac ischemia: the MAGNETO trial. *Am Heart J Plus.* (2024) 40:100372. doi: 10. 1016/j.ahjo.2024.100372

40. Wu T, Zhao X, Feng L, Yang S, Xing H, Ma Z, et al. Comparison of magnetocardiography and coronary computed tomographic angiography for detection of coronary artery stenosis and the influence of calcium. *Eur Radiol.* (2025) 35(8):4775–85. doi: 10.1007/s00330-025-11389-4

41. Zhang H, Ma Z, Mi H, Jiao J, Dong W, Yang S, et al. Diagnostic value of magnetocardiography to detect abnormal myocardial perfusion: a pilot study. *Rev Cardiovasc Med.* (2024) 25(10):379. doi: 10.31083/j.rcm2510379

42. Saleh A, Brachmann J. Utility of magnetocardiography and stress speckle tracking in detection of coronary artery disease. *Diagnostics (Basel).* (2024) 14(17):1893. doi: 10.3390/diagnostics14171893